These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25342444)

  • 1. Ustekinumab improves psoriasis without suppressing tumor antigen-specific cytotoxic T lymphocytes.
    Narita M; Nishizawa Y; Iwaya S; Oiwa E; Iwabuchi M; Uchiyama T; Matsuyama A; Masuko M; Takahashi M
    Int Arch Allergy Immunol; 2014; 165(1):52-60. PubMed ID: 25342444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.
    Iwabuchi M; Narita M; Uchiyama T; Iwaya S; Oiwa E; Nishizawa Y; Hashimoto S; Bonehill A; Kasahara N; Takizawa J; Takahashi M
    Mol Med Rep; 2015 Aug; 12(2):2443-50. PubMed ID: 25936433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
    Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity.
    Tsuda K; Yamanaka K; Kondo M; Matsubara K; Sasaki R; Tomimoto H; Gabazza EC; Mizutani H
    PLoS One; 2012; 7(12):e51819. PubMed ID: 23251632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
    Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
    Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
    Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
    Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of antigen-specific cytotoxic T lymphocytes using a leukemic plasmacytoid dendritic cell line as antigen presenting cells.
    Yamahira A; Narita M; Nakamura T; Watanabe N; Kaji M; Taniguchi T; Hashimoto S; Furukawa T; Toba K; Aizawa Y; Kuzushima K; Takahashi M
    Leuk Res; 2011 Jun; 35(6):793-9. PubMed ID: 21216464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.
    Brodmerkel C; Wadman E; Langley RG; Papp KA; Bourcier M; Poulin Y; Ho V; Guenther L; Kunynetz R; Nigen S; Vender R; Wasel N; Hsu MC; Szapary P
    J Drugs Dermatol; 2013 Oct; 12(10):1122-9. PubMed ID: 24085047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients.
    Gao L; Xue SA; Hasserjian R; Cotter F; Kaeda J; Goldman JM; Dazzi F; Stauss HJ
    Transplantation; 2003 May; 75(9):1429-36. PubMed ID: 12792492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes.
    Azuma T; Otsuki T; Kuzushima K; Froelich CJ; Fujita S; Yasukawa M
    Clin Cancer Res; 2004 Nov; 10(21):7402-12. PubMed ID: 15534117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.
    Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels WS; Jäger E; Bader P
    Leukemia; 2009 Sep; 23(9):1634-42. PubMed ID: 19357702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.
    Nakajima H; Oka Y; Tsuboi A; Tatsumi N; Yamamoto Y; Fujiki F; Li Z; Murao A; Morimoto S; Hosen N; Shirakata T; Nishida S; Kawase I; Isaka Y; Oji Y; Sugiyama H
    Vaccine; 2012 Jan; 30(4):722-9. PubMed ID: 22133512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
    Kimball AB; Papp KA; Wasfi Y; Chan D; Bissonnette R; Sofen H; Yeilding N; Li S; Szapary P; Gordon KB;
    J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1535-45. PubMed ID: 23279003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
    Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
    Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to ustekinumab in psoriasis patients.
    Sandoval LF; Huang KE; Feldman SR
    J Drugs Dermatol; 2013 Oct; 12(10):1090-2. PubMed ID: 24085042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Wang ZD; Li D; Huang XJ
    Chin Med J (Engl); 2010 Apr; 123(7):912-6. PubMed ID: 20497687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wilms' tumor 1-specific cytotoxic T lymphocytes can be expanded from adult donors and cord blood.
    Krishnadas DK; Stamer MM; Dunham K; Bao L; Lucas KG
    Leuk Res; 2011 Nov; 35(11):1520-6. PubMed ID: 21774984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.